Waters (WAT) is trading higher as the market digests its May 5, 2026 first-quarter 2026 earnings update and looks for confirmation that fundamentals and integration execution remain on track following the recently announced combination with BD’s Biosciences and Diagnostic Solutions unit. The stock’s move also appears tied to expectations that Waters’ Q1 results land within the company’s prior outlook range and that management provides constructive commentary on synergy realization and commercial initiatives.

Heading into the quarter, Waters had guided to Q1 2026 adjusted EPS of $2.25–$2.35 and combined-company revenue of $1.198 billion to $1.211 billion, alongside full-year 2026 adjusted EPS of $14.30–$14.50. Investors have been especially sensitive to any read-through on the acquired BD business trajectory, the pace of revenue and cost synergy capture, and whether instrument replacement-cycle demand and Chemistry growth can offset any pockets of softness in academic/government and ongoing software/subscription-model transitions.

The most market-moving items from the May 5 earnings call are likely to be: (1) any change to 2026 guidance (up or down), (2) quantified progress on cost and revenue synergies tied to the BD combination, (3) margin commentary as integration costs, mix, and pricing flow through results, and (4) end-market signals in Pharma/Industrial demand and recurring revenue (chemistries and service). A clearer integration narrative—especially around go-to-market initiatives and service attachment—can quickly shift investor confidence, even if headline quarterly numbers are close to consensus.